A phase 2 study of the combination of gemcitabine and cisplatin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines with/ without taxanes

Hematology/ Oncology and Stem Cell Therapy

Volumn 5, Issue 1, 2012, Pages 42-48

  Kohail, Hanna ^a   Shehata, Samir ^b   Mansour, Omar ^c   Gouda, Youssri ^a   Gaafar, Rabbab ^c   Hamid, Thoraya Abdel ^c   Nowieam, Saiid El ^a   Al Khodary, Ahmed ^c   El Zawahry, Heba ^c   Wareth, Ahmed Abdel ^c   Halim, Iman Abdel ^d   Taleb, Fouad Abou ^e   Hamada, Emad ^f   Barsoum, Mohsen ^c   Abdullah, Mohamed ^f   Meshref, Mohamed ^f  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b ASSIUT UNIVERSITY   (Egypt)

^c NATIONAL CANCER INSTITUTE   (Egypt)

^d MANSOURA UNIVERSITY   (Egypt)

^e ZAGAZIG UNIVERSITY   (Egypt)

^f CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CISPLATIN; GEMCITABINE; TAXANE DERIVATIVE;

ABDOMINAL CRAMP; ACUTE HEART INFARCTION; ADULT; AGED; ALOPECIA; ANEMIA; APPETITE DISORDER; ARTICLE; ASTHENIA; BONE DISEASE; BREAST CANCER; CANCER GROWTH; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTRITIS; HEART ARREST; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; ULCER; VOMITING;

EID: 84859094848     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.5144/1658-3876.2012.42     Document Type: Article

References (24)

1. Elatar I. Cancer registration, NCI Egypt 2001. National Cancer Institute, Cairo, Egypt, 2002. Available from: http://www.nci.edu.eg/Journal/nci2001%20.pdf. Accessed May 30, 2011.
2. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol. 1995;13:2731-6.
3. Possinger K, Kaufmann M, Coleman R, Stuart NS, Helsing M, Ohnmacht U, Arning M. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs. 1999;10:155-62.
4. Akrivakis K, Grunewald R, Mergenthaler HG. Gemcitabine (Gem) phase II study in advanced breast cancer. Onkologie. 1995;18(suppl. 2):101.
5. M Blackstein, CL Vogel, R Ambinder, J Cowan, P Pearce, J Iglesias, FA Dorr. Phase II study of gemcitabine in patients with metastatic breast cancer. Proc Am Soc Clin Oncol. 1996;15:(abstr 135).
6. Spielmann M, Kalla S, Llombart-Cussac A, Espie M, Namer M, Ferrero JM, Cuvier C, Fumoleau P, Ponzio A, Kayltalire L, Pouillart P. Activity of gemcitabine in metastatic breast cancer (MBC) patients previously treated with anthracyclinecontaining regimens Eur J Cancer. 1997;33(suppl. 8):S149 (abstr 663).
7. Brodowicz T, Kostler WJ, Möslinger R, Tomek S, Vaclavik I, Herscovic V, Wiltschke C, Steger GG, Wein W, Seifert M, Kubista E, Zielinksi CC. Single-agent gemcitabine as second-and third-line treatment in metastatic breast cancer. Breast. 2000;9:338-42.
8. Gerson R, Serrano A, Villalobos A, Ortiz C, Sánchez-Forgach E. Gemcitabine response in advanced breast cancer in relation to immunohistochemical factors. Proc Am Soc Clin Oncol. 2000; 19:(abstr 572).
9. Akrivakis K, Schmid P, Flath B, Schweigert M, Sezer O, Mergenthaler HG, Possinger K. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anti-cancer Drugs. 1999;10:525-31.
10. Schmid P, Akrivakis K, Flath B, Grosse Y, Sezer O, Mergenthaler HG, Possinger K. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs. 1999;10:625-31.
11. Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol. 2000;18:2245-9.
12. Chaudhry S, Abdel-Rahman H, Patil R, Mansour R, Mills G, Burton G. Prospective phase II study of weekly cisplatin-gemcitabine in refractory metastatic breast cancer (RM-BC). Proc Am Soc Clin Oncol. 2000;19:(abstr 430).
13. Doroshow J, Tetef M, Margolin K, Somlo G, Frankel P, Longmate J, Synold T, Gandara D, Lenz HJ, Albain K. Significant activity of gemcitabine (Gem) and cisplatin (Ddp) in both heavily (H) and minimally (M)-pretreated metastatic breast cancer (Mbc) patients (Pts): A California Cancer Consortium/Loyola Univ. Chicago trial. Proc Am Soc Clin Oncol. 2000; 19:(abstr 609H).
14. Miller AB, Hoogenstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-14.
15. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, Tharavichitkul E, Trakultivakorn H, Somwangprasert A, Sumitsawan S, Srisukho S, Watcharachan K, Sukthomya V. Gemcitabine plus cisplatin (GC): a salvage regimen for advanced breast cancer patients who failed anthracycline and/or taxane therapy. Gan To Kagaku Ryoho. 2006;33:761-6.
16. Ajarim D, Ezzat A, Bazarbashi S, Rahal M, El Foudeh M, Pai C, Raja M. Gemcitabine plus cisplatin combination as second-line treatment in patients with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol. 2004;22:A774.
17. El Khodary A, Gouda Y, Al Noweim S, Kohail H, Gaafar R, Zawahry H, Wareth AA, Mansour O, Shehata S, Hamid TA. Gemcitabine plus cisplatin in patients with locally advanced or metastatic breast cancer (MBC) who failed prior anthracyclines therapy +/taxanes. J Clin Oncol. 2004;22 (Suppl):(abstr 769).
18. Xu B, Li K, Liu D. Phase II trial of gemcitabine and cisplatin in anthracycline-resistant metastatic breast cancer. Proc Am Soc Clin Oncol. 2003;22:(abstr 211).
19. Galvez CA, Galmarini F, Curie M. Monthly cisplatin and gemcitabine as second line chemotherapy for patients with advanced breast cancer. Breast Cancer Res Treat. 2000;64:81 (abstr 324).
20. Burch PA, Mailliard JA, Hillman DW, Perez EA, Krook JE, Rowland KM, veeder MH, Cannon MW, Ingle JN. Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: A North Central Cancer Treatment Group trial. Am J Clin Oncol. 2005;28:195-200.
21. Fuentes de la Pena H, Tellez E, Bastarrachea J, Capdeville D. Gemcitabine plus cisplatin as a palliative treatment in metastatic or refractory breast cancer (MRBC). Proc Am Soc Clin Oncol. 2001;20:(abstr 1990).
22. Gerson R, Fuentes H, Serrano A, Villalobos A. Gemcitabine and cisplatin (GC) for metastatic breast cancer (BC). J Clin Oncol. 2005;23(16S):(abstr 871).
23. Heinemann V, Stemmler HJ, Wohlrab A, Bosse D, Losem C, Kahlert S, Rauthe G. High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline-and taxane-pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2006;57:640-6.
24. Moiseyenko V, Protsenko S, Orlova R, Ermakova N, Mikhailitchenko T, Semenova A, Bloshchinskaya A. Phase II study of the combination of gemcitabine (G) and cisplatin (C) in anthracyclineresistant breast cancer patients. Int J Cancer. 2002 100;(suppl 13):196 (abstr P172).